Primera especialidad
Permanent URI for this communityhttps://hdl.handle.net/20.500.14595/820
Browse
Browsing Primera especialidad by Author "Andrea Marcela Zuluaga-Liberato"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item Prevention and treatment of cisplatin-induced ototoxicity in adults: A systematic review(2023-09-23) Juan Esteban Correa-Morales; Sara Giraldo-Moreno; Nidia Mantilla-Manosalva; Laura Cuellar-Valencia; Oscar Felipe Borja-Montes; Lennis Jazmin Bedoya-Muñoz; María Fernanda Iriarte-Aristizábal; Elias Quintero-Muñoz; Andrea Marcela Zuluaga-LiberatoObjectives: Ototoxicity is a common disabling side effect of platinum-based chemotherapy. This study aimed to assess the evidence on the management of platinum-induced ototoxicity in adult cancer patients. Methods: Four databases were searched up to 1 November 2022. Original studies were included if they reported on a pharmacologic or non-pharmacologic intervention to prevent or treat platinum ototoxicity in adults. The articles' quality was assessed via two grading scales. Results: Nineteen randomised controlled trials and five quasi-experimental studies with 1673 patients were analysed. Eleven interventions were identified, nine pharmacological and two non-pharmacological. Six of the interventions (sodium thiosulphate, corticoids, sertraline, statins, multivitamins and D-methionine) showed mild benefits in preventing cisplatin-induced ototoxicity. Only one trial assessed corticoids as a potential treatment. Overall, only six trials were deemed with a low risk of bias. The majority of studies inadequately documented intervention-related adverse effects, thereby limiting safety conclusions. Conclusions: Current interventions have mild benefits in preventing cisplatin-induced ototoxicity in adult cancer patients. Sodium thiosulphate is the most promising intervention as a preventive strategy. Rigorous, high-quality research is warranted, encompassing an evaluation of all potential symptoms and innovative treatment modalities. Keywords: chemotherapy-related adverse events; cisplatin-induced ototoxicity; hearing loss; otoprotection; platinum chemotherapy.